We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.95B
AUM Growth
-$162M
Cap. Flow
+$94.6M
Cap. Flow %
3.21%
Top 10 Hldgs %
48.26%
Holding
91
New
14
Increased
7
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.4M
2
CGEM icon
Cullinan Oncology
CGEM
+$43.6M
3
NUVB icon
Nuvation Bio
NUVB
+$39.6M
4
CNTB
Connect Biopharma Holdings
CNTB
+$35.4M
5
IMVT icon
Immunovant
IMVT
+$26.4M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$116M
2
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.3M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$25.9M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$19.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Financials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$343M 11.62%
2,000,000
+234,440
+13% +$46.4M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$266M 9.02%
764,188
-350,000
-31% -$116M
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$160M 5.42%
3,484,264
+175,000
+5% +$7.85M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$153M 5.18%
2,075,905
– –
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$149M 5.04%
4,345,016
– –
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$81.9M 2.78%
1,094,000
– –
PMVP icon
7
PMV Pharmaceuticals
PMVP
$59.2M
$74.6M 2.53%
2,268,236
– –
SPRY icon
8
ARS Pharmaceuticals
SPRY
$509M
$73.1M 2.48%
1,675,377
– –
RCKT icon
9
Rocket Pharmaceuticals
RCKT
$340M
$65M 2.21%
1,466,051
– –
RCUS icon
10
Arcus Biosciences
RCUS
$3.55B
$58.5M 1.99%
2,084,883
– –
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$55.5M 1.88%
400,000
– –
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.42B
$51.8M 1.76%
2,202,812
– –
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.69B
$51.2M 1.73%
2,287,782
– –
BDTX icon
14
Black Diamond Therapeutics
BDTX
$96.8M
$48.9M 1.66%
2,014,858
– –
CYTK icon
15
Cytokinetics
CYTK
$10.5B
$48.8M 1.66%
2,100,000
– –
ARGX icon
16
argenx
ARGX
$53.4B
$47.1M 1.6%
170,926
– –
NUVB icon
17
Nuvation Bio
NUVB
$2.2B
$45.4M 1.54%
4,341,009
+3,541,009
+443% +$39.6M
CGEM icon
18
Cullinan Oncology
CGEM
$1.01B
$44.8M 1.52%
+1,074,082
New +$43.6M
RLAY icon
19
Relay Therapeutics
RLAY
$4.1B
$44.7M 1.52%
1,294,132
– –
DBVT
20
DBV Technologies
DBVT
$799M
$40.2M 1.36%
753,460
– –
MRUS
21
DELISTED
Merus
MRUS
$39.7M 1.35%
1,900,000
+472,151
+33% +$10.9M
CNTB
22
Connect Biopharma Holdings
CNTB
$127M
$38.5M 1.31%
+2,081,323
New +$35.4M
NRIX icon
23
Nurix Therapeutics
NRIX
$2.41B
$38.1M 1.29%
1,224,892
– –
AMRN
24
Amarin Corp
AMRN
$299M
$37.3M 1.26%
300,000
– –
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$37.2M 1.26%
2,400,000
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Boxer Capital held 91 positions worth $2.95B, down 5.2% from $3.11B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital deployed $94.6M of net new capital in Q1 2021, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Cullinan Oncology: 1,074,082 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $116M trimmed.

  • Boxer Capital's largest Q1 2021 buy was Cullinan Oncology: 1,074,082 shares worth $44.8M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q1 2021, an estimated $46.4M increase.
  • Boxer Capital's biggest Q1 2021 reduction was BeOne Medicines Ltd, cutting an estimated $116M.
  • Boxer Capital fully exited Pandion Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $31.3M.
  • Boxer Capital's ten largest holdings make up 48% of its $2.95B portfolio in Q1 2021.
  • Boxer Capital opened 14 new positions and closed 6 in Q1 2021.
  • Boxer Capital's portfolio value fell 5.2% quarter-over-quarter to $2.95B.

Based on Boxer Capital's 13F filing for Q1 2021, filed 17 May 2021.